In force Publication date 14 Jan 16
Detection of Sotatercept (ACE-011, ActRIIA-IgGI) in human urine and blood – Protocols for initial and confirmatory doping testing
Project Title: Detection of Sotatercept (ACE-011, ActRIIA-IgGI) in human urine and blood – Protocols for initial and confirmatory doping testing
Researchers: Dr. C. Reichel, Dr. A. Huber, Dr. V. Scheiblhofer
Institutions: Seibersdorf Labor GmbH, Austria
Year accepted: 2014
Summary: Sotatercept (ACE-011, ActRIIA-IgGI), a fusion protein consisting of the extracellular domain of ActRIIA receptor and the Fc-part of human immunoglobulin G1 (IgG1), is capable of acting as ActRIIA ligand trap, and was primarily developed as pharmaceutical for enhancing bone mineralisation in order to revert osteoporosis. However, aside from increasing bone mineral density, it was discovered that Sotatercept also stimulates erythropoiesis in a dose dependant manner leading to an increase in red blood cell counts. Sotatercept is currently intensely investigated in several phase II clinical trials
Available in 1 language.